AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Interferon gamma receptor 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

P15260

UPID:

INGR1_HUMAN

Alternative names:

CDw119; Interferon gamma receptor alpha-chain

Alternative UPACC:

P15260; B4DFT7; E1P587; Q53Y96

Background:

Interferon gamma receptor 1 (IFNGR1), also known as CDw119, plays a pivotal role in immune responses against infections and tumors. It forms a functional receptor with IFNGR2, crucial for activating immune cells and enhancing antigen presentation. Upon binding with interferon gamma, IFNGR1 initiates a cascade involving JAK1 and JAK2 phosphorylation, leading to STAT1 activation and gene transcription essential for antimicrobial, antiviral, and antitumor responses.

Therapeutic significance:

Mutations in IFNGR1 are linked to Immunodeficiency 27A and 27B, conditions characterized by impaired interferon-gamma mediated immunity, leading to susceptibility to mycobacterial diseases. Understanding the role of IFNGR1 could open doors to potential therapeutic strategies for these immunodeficiencies, offering hope for targeted treatments that restore immune function and prevent severe infections.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.